September 2026 has been one of the busiest months for mainboard IPO activity in India’s post-monsoon calendar, with real estate, healthcare, and chemical company IPOs hitting the market in quick succession. Into this active window steps the Prasol Chemicals IPO — a ₹500 crore mainboard book-built issue from one of India’s specialty chemicals manufacturers, priced at ₹643–₹676 per share and opening for subscription on September 8, 2026.
What retail investors must understand before applying is that this Prasol Chemicals IPO channels ₹420 crore (84%) of the ₹500 crore total back to existing promoters through an offer for sale, while the company itself raises only ₹80 crore in fresh capital. Prasol Chemicals Limited brings genuine financial momentum to the listing — PAT estimated at ~₹83 crore in FY26, up ~91% from FY25 — but the overwhelming promoter-exit component creates a risk profile that differs materially from most September 2026 mainboard peers.
What Is Prasol Chemicals Limited — Business, Products, and Industry Position
Prasol Chemicals Limited, incorporated in 1992 and founded by Mr. Nishith Shah, is headquartered in Navi Mumbai with a manufacturing facility at Khopoli, Maharashtra, producing 150+ specialty chemicals across two core technology platforms: acetone derivatives and phosphorous derivatives. The company’s products serve agrochemicals, pharmaceuticals, home and personal care, paints and coatings, lubricant additives, mining chemicals, and oilfield and refinery applications.
Export to 50+ countries diversifies the company against India-specific demand cycles — international revenue is a genuine structural positive. Revenue grew from ₹876.57 crore in FY24 to ₹1,012.49 crore in FY25, with Q1 FY26 (April–June 2025) revenue of ₹319.56 crore annualising to approximately ₹1,235 crore for the full year.
India’s specialty chemicals sector sits at the intersection of three structural tailwinds — China+1 supply chain diversification, PLI-scheme manufacturing incentives, and pharmaceutical raw material localisation — the same drivers behind the broader private investment in India sectors revival that accelerated in FY26 across capital-intensive manufacturing.
Prasol Chemicals IPO Date, Price Band, and Complete Subscription Details
The Prasol Chemicals IPO opens on September 8, 2026 and closes on September 10, 2026 at an IPO price band of ₹643–₹676 per share (face value ₹10).
Application Details by Category (at ₹676 upper band):
| Category | Lots | Shares | Application Amount |
|---|---|---|---|
| Retail – Minimum | 1 lot | 22 shares | ₹14,872 |
| Retail – Maximum | 13 lots | 286 shares | ₹1,93,336 |
Investor Category Reservation:
| Category | Allocation |
|---|---|
| QIB | 50% |
| NII / HNI | 15% |
| Retail Individual Investor (RII) | 35% |
The 35% retail quota is the standard mainboard floor — unlike September 2026 batch peers Purple Style Labs and Rays of Belief, which allocated just 10% to retail. Applications submit via ASBA or UPI through a broker or bank platform; UPI mandate approval must complete before the September 10 cut-off. DAM Capital Advisors Ltd. leads the book-building as BRLM; KFin Technologies Ltd. is the registrar. Allotment finalises September 11, 2026, with listing on BSE and NSE on September 16, 2026.
The Number That Defines This Issue — ₹420 Crore OFS vs ₹80 Crore Fresh
In the Prasol Chemicals IPO, 84% of the ₹500 crore total issue goes directly to selling promoters through an offer for sale — not to the company. Ten named promoters (Nishith Rajnikant Shah, Gaurang Natwarlal Parikh, Dhaval Nalin Parikh, Pankil Nishith Dharia, Sachin Jatin Parikh, Rakesh Gupta, Nishith Rasiklal Dharia, Kunal Tushar Dharia, Suketu Navinchandra Parikh, and Usha Rajnikant Shah) sell 62.13 lakh shares at this valuation, with their pre-IPO stake at 89.20%.
Objects of Issue (Fresh Issue ₹80 crore):
| Purpose | Amount (₹ Crore) |
|---|---|
| Repayment / prepayment of borrowings | ₹60 |
| General corporate purposes | ₹20 |
The fresh issue itself is almost entirely consumed by debt repayment (₹60 crore) and general corporate purposes (₹20 crore) — zero fresh capital funds capacity expansion, R&D, new product development, or acquisitions. Prasol’s post-IPO growth depends fully on organic business momentum, not IPO capital.
High OFS ratios do not automatically signal a poor outcome — several OFS-heavy IPOs have listed and traded strongly when the business justified the price. The material point is this: an investor applying at ₹676 per share is buying from promoters who chose to monetise at this price; every Prasol Chemicals IPO review must weigh that fact alongside the earnings trajectory and sector tailwinds.
Prasol Chemicals IPO Financials — Revenue Growth, PAT Recovery, and Margin Trajectory
The financial trajectory behind the Prasol Chemicals IPO spans four years and tells two distinct stories: a sharp margin collapse in FY24, followed by a genuine and accelerating recovery through FY25 and into FY26. Investors who see only the FY26 headline numbers without the FY24 context are missing the most important risk data point in the financial table.
Financial Performance (FY23–FY26):
| Year | Revenue (₹ Cr) | PAT (₹ Cr) | PAT Margin | EBITDA Margin |
|---|---|---|---|---|
| FY23 | ₹930.08 | ₹48.59 | 5.22% | 9.35% |
| FY24 | ₹876.57 | ₹18.13 | 2.07% | 6.91% |
| FY25 | ₹1,012.49 | ₹43.57 | 4.30% | 8.67% |
| FY26 (est.) | ~₹1,235 | ~₹83 | ~6.7% | ~12.71%* |
*FY26 based on company-reported 22% revenue growth and 91% PAT growth vs FY25. Q1 FY26 actuals: Revenue ₹319.56 Cr, PAT ₹24.34 Cr, EBITDA Margin 12.71%. Full-year FY26 audited results pending.
FY24’s PAT collapsed 63% — from ₹48.59 crore to ₹18.13 crore — as acetone and phosphorous feedstock costs spiked and EBITDA margin fell from 9.35% to 6.91%. FY25 saw input costs normalise, and FY26’s Q1 EBITDA margin of 12.71% (well above the FY25 full-year 8.67%) suggests strong operating leverage when feedstock costs are benign. Average RoNW: 23.17%; Adjusted RoCE (FY25): 14.95%; NAV per share: ₹140.81 (December 31, 2025); P/BV at ₹676: ~2.44x.
Prasol Chemicals IPO Valuation — No Listed Peers, P/BV as the Only Official Anchor
The SEBI offer documents for this issue confirm that Prasol Chemicals has no listed comparable companies in India — the RHP contains no peer comparison table, making conventional P/E benchmarking impossible. The only official valuation reference is P/BV: ₹676 / ₹140.81 NAV = ~2.44x.
For context (not direct comparison), listed specialty chemicals companies like Aarti Industries, Vinati Organics, and Deepak Nitrite trade at 25–40x trailing P/E. At estimated FY26 PAT of ~₹83 crore on a post-IPO market cap of approximately ₹1,862 crore (at ₹676 per share), the implied P/E is roughly 22–23x — within specialty chemicals sector range, but entirely contingent on FY26 earnings being confirmed by audited results. The FY24 precedent — a 63% PAT collapse in a single year — demonstrates that this business’s margins can move sharply; a 2.44x P/BV floor provides limited protection if that pattern recurs in FY27.
OFS Structure Comparison — Where Prasol Chemicals IPO Sits in the September 2026 Batch
Context matters in any IPO analysis, and the OFS-to-fresh-issue ratio is the most revealing structural metric across September 2026 mainboard issues.
OFS vs Fresh Issue — September 2026 Mainboard IPO Batch:
| Company | Total Issue (₹ Cr) | Fresh Issue (₹ Cr) | OFS (₹ Cr) | OFS % | OFS Seller |
|---|---|---|---|---|---|
| Rays of Belief | ₹125 | ₹125 | ₹0 | 0% | None |
| Pranav Constructions IPO | ₹351 | ₹316 | ₹35 | 10% | Investor (non-promoter) |
| Prasol Chemicals IPO | ₹500 | ₹80 | ₹420 | 84% | Promoters |
At 84% OFS with promoters as sellers, this issue sits at the maximum end of the promoter-exit spectrum in its peer window — contrasting sharply with Pranav Constructions (10% OFS by a non-promoter investor) and Rays of Belief (zero OFS, 100% fresh issue). This table is not presented as a negative judgment: it is information that every retail investor applying to the Prasol Chemicals IPO subscription deserves to evaluate explicitly before committing capital.
Prasol Chemicals IPO GMP Today — Status and What to Track
The Prasol Chemicals IPO GMP had not commenced as of September 3–7, 2026 — grey market activity typically emerges 1–2 days after the subscription window opens for mainboard issues, and no grey market premium was reported before September 8.
Once subscription opens, GMP data for this IPO will appear on platforms like Chittorgarh and IPO Watch. For a ₹500 crore issue with 84% OFS and no listed peers, the grey market premium carries an outsized signalling value — HNI and dealer markets explicitly price the OFS-structure risk into their premium. A flat or negative GMP would reflect informal market discomfort with the structure more than a judgement on business quality; a positive GMP above ₹30–₹40 (4–6% on ₹676) would signal that the IPO valuation is finding informal-market acceptance. GMP is informal and unregulated; SEBI has no oversight over grey market activity, and the figure does not predict the actual listing price on September 16. Live category-wise subscription data updates in real time at nseindia.com and bseindia.com.
Five Risks to Evaluate Before the September 10 Close
OFS dominance — investors are buying from promoters, not funding the company. Of the ₹500 crore raised by this issue, ₹420 crore goes directly to selling promoters who chose to reduce their position at ₹676 per share; the company receives zero rupees from the OFS and retains only ₹80 crore of the total subscription amount.
PAT has a proven history of sharp downswings. Prasol Chemicals Limited’s PAT fell 63% in a single year — from ₹48.59 crore (FY23) to ₹18.13 crore (FY24) — before recovering in FY25 and surging in FY26; the FY26 recovery is real, but precedent for sudden profit compression is established in the company’s own recent history.
No listed peers makes valuation anchoring investor-dependent. With no comparable listed company per SEBI documents, investors cannot benchmark ₹676 against an industry P/E multiple — the only official reference is P/BV at ~2.44x, which requires independent assessment of whether the earnings trajectory justifies the premium to book value.
Fresh proceeds deploy zero growth capital. The ₹80 crore fresh issue repays debt (₹60 crore) and funds general purposes (₹20 crore); no IPO capital goes toward new manufacturing capacity, product development, or acquisitions — all FY27 and beyond growth must come from internal generation.
Specialty chemicals margins are feedstock-price-sensitive. Prasol’s EBITDA margin swung from 6.91% (FY24) to 12.71% (Q1 FY26) — a near-doubling driven by feedstock cost normalisation; any reversal in acetone or phosphorous input prices in FY27 could compress margins and reverse the FY26 PAT gains.
What Retail Investors Should Do Before Applying to Prasol Chemicals IPO 2026
Apply at the cut-off price (₹676) to stay eligible for allotment. In all mainboard book-building issues, bids placed below the final closing price are rejected outright — applying at cut-off ensures the application remains in the allotment pool regardless of where the book closes within the band.
Read the OFS section of the RHP before applying to the Prasol Chemicals IPO 2026 subscription. The RHP details each selling promoter’s name, the number of shares each offloads, and their pre-IPO and post-IPO holdings — the post-IPO promoter stake percentage is the single most useful data point for assessing founders’ long-term alignment with the listed company.
Track the Prasol Chemicals IPO GMP from September 8 afternoon on verified platforms. Once grey market trading begins, a GMP above ₹30–₹40 (4–6% on ₹676) suggests informal markets are comfortable with the pricing despite the OFS structure; a flat or negative GMP is a material signal worth weighing before allotment.
Watch QIB subscription coverage by September 8 afternoon on NSE bid monitoring. With QIBs allocated 50% of this issue — the largest category — strong Day 1 institutional demand validates the pricing thesis more reliably than any informal market indicator.
Check the Prasol Chemicals IPO allotment date status on September 11 via KFin Technologies. Allotment finalises on September 11, 2026 at the KFin Technologies registrar portal (kfintech.com) — check using PAN or application number; demat credit and refunds follow before the September 16 listing.
Frequently Asked Questions
What is the Prasol Chemicals IPO GMP today?
The Prasol Chemicals IPO GMP had not commenced as of September 3–7, 2026 — the grey market typically activates 1–2 days into the subscription window. GMP data will appear on platforms like Chittorgarh and IPO Watch from September 8 onward. GMP is unregulated and informal; SEBI does not oversee grey market activity, and no GMP figure guarantees the actual listing price on September 16, 2026.
What is the Prasol Chemicals IPO allotment date and listing schedule?
The Prasol Chemicals IPO subscription runs September 8–10, 2026. Allotment finalises September 11, 2026. Demat credit and refunds follow before listing. The issue lists on BSE and NSE on September 16, 2026.
Is 84% OFS a reason to avoid this IPO?
A high OFS ratio warrants scrutiny but does not automatically make an IPO a poor investment — the key question is whether the business quality and earnings trajectory justify the price at which promoters are choosing to exit. In this case, Prasol Chemicals Limited’s 91% estimated PAT growth in FY26 is a genuine positive; the OFS structure is a risk factor to weigh alongside it. Consult a SEBI-registered financial advisor before any investment decision.
How does an investor track live Prasol Chemicals IPO subscription data?
Category-wise data (QIB 50%, NII 15%, Retail 35%) updates continuously on the NSE bid monitoring dashboard and BSE IPO subscription page from September 8, 2026. Check nseindia.com or bseindia.com directly for live figures.
Why does this IPO have no listed peers in the comparison table?
SEBI offer documents confirm that Prasol Chemicals Limited — a producer of acetone derivatives and phosphorous derivatives — has no directly comparable listed company in India. The RHP includes no peer P/E table, making P/BV of ~2.44x at ₹676 the primary official valuation benchmark.
Strong Earnings Recovery, 84% Promoter Exit, and No Listed Peers — The Prasol Chemicals IPO Asks Investors to Weigh Both Sides
The Prasol Chemicals IPO arrives with three decades of specialty chemicals manufacturing behind it, a genuine PAT recovery story (from ₹18.13 crore in FY24 to an estimated ~₹83 crore in FY26), and sector tailwinds that are structural rather than cyclical. The structural concern is equally concrete: 84% of the ₹500 crore goes to selling promoters, the company receives only ₹80 crore (mostly for debt repayment), and the RHP offers no listed peer for valuation benchmarking.
Retail investors with conviction on India’s specialty chemicals sector and a medium-term holding horizon have a coherent thesis — but it requires independent valuation work that a standard P/E comparison cannot shortcut here. The 91% estimated PAT growth in FY26 is real; so is the FY24 precedent where PAT fell 63% in twelve months. Both facts belong in the same sentence when assessing this issue.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. IPO investments are subject to market risks. This site is not SEBI registered. All financial data sourced from company filings, SEBI filings, and publicly available IPO documents. Readers are advised to consult a SEBI-registered financial advisor before making any investment decisions.